News

Significant Milestones Achieved in PAS-004 Toxicity Studies

Significant Milestones Achieved in PAS-004 Toxicity Studies

Encouraging Results from PAS-004 Chronic Toxicity Studies

Pasithea Therapeutics Corp. (NASDAQ: KTTA) is making significant strides in the biotechnology field with the recent completion of chronic toxicity studies for PAS-004, an innovative macrocyclic MEK inhibitor. This compound is being developed to treat neurofibromatosis type 1 (NF1) and various cancer-related conditions. The studies, which included both rats and dogs, represent a major advancement and have produced promising results that support the company's upcoming clinical efforts.

Study Findings Reveal Strong Safety Profile

The extensive studies were conducted over a prolonged period, confirming previous results from 28-day toxicity assessments. By administering PAS-004 daily for six months to rats and extending the duration to nine months for dogs, the research demonstrated a reassuring safety profile in both species. The study with dogs established the no adverse effect level (NOAEL) at 0.5 mg/kg. This noteworthy finding reinforces PAS-004's consistent safety profile and its potential as an effective cancer treatment.

Insights on Long-term Dosing

The studies indicated that long-term dosing of PAS-004 not only aligned with the previously established safety profile but also appeared to correlate with effective engagement of the targeted pathways. Dosages below the NOAEL are anticipated to lead to significant reductions in pERK, a crucial element in tumor growth pathways. The robust data emerging from these studies further emphasizes PAS-004's potential as a leading option among MEK inhibitors available in the market.

Clinical Applications and Future Trials

With primarily the crystal form of PAS-004 being used in human clinical trials, the consistent adverse event profile observed with its amorphous counterpart suggests promising possibilities as the company gears up for patient dosing. The insights gained from these studies are expected to facilitate more refined clinical practices, effectively targeting cancer cells while minimizing side effects, which is a major concern with traditional therapies.

Leadership Insights

Dr. Tiago Reis Marques, the CEO of Pasithea, expressed his optimism about PAS-004's potential, stating that prolonged suppression of the Mitogen Associated Protein Kinase (MAPK) pathway could enhance its efficacy. He also emphasized the company's eagerness to share further data on PAS-004, particularly initial interim results from their Phase 1 clinical trials, which are expected to provide critical insights into its pharmacokinetic (PK) and pharmacodynamic (PD) profiles.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics is a prominent player in the clinical-stage biotechnology sector, dedicated to developing innovative solutions for central nervous system (CNS) disorders and RASopathies. The company's skilled team, made up of experts in neuroscience and drug development, is on an urgent mission to discover new treatments for debilitating neurological conditions. PAS-004 is just one of their ambitious projects, which also includes research on solid tumors and diseases like Amyotrophic Lateral Sclerosis (ALS).

Frequently Asked Questions

What is PAS-004 developed by Pasithea Therapeutics?

PAS-004 is a next-generation macrocyclic MEK inhibitor aimed at treating neurofibromatosis type 1 (NF1) and other cancers, and it is currently undergoing clinical trials.

What were the findings of the chronic toxicity studies?

The studies revealed a favorable safety profile for PAS-004, consistent with earlier 28-day study results, and established the NOAEL level at 0.5 mg/kg for dogs.

How long were the PAS-004 studies conducted?

The studies were carried out over six months in rats and nine months in dogs, providing comprehensive data on its safety and long-term effects.

What does the NOAEL mean for PAS-004?

NOAEL stands for No Adverse Effect Level; it indicates the highest dose at which no harmful effects were observed, helping to guide safe dosing in future clinical trials.

What are Pasithea's future plans regarding PAS-004?

Pasithea intends to share more information about PAS-004, including initial results from its first-in-human Phase 1 clinical study, which are expected within the next quarter.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 101

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 79

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Sungrow Puts Storage Safety and Deployment on Display

Updated Category News Views 129

Fire-test footage is not usually the thing that grabs a room in Las Vegas, but Sungrow made it the centerpiece at RE+ 2026 for a reason. Energy storage has no shortage of glossy promises; what it needs is proof that equipment can handle the ugly stuff. Sungrow used the show to pitch a broader North American lineup, yet the PowerTitan 3.0 battery system and its large-scale...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 99

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Vanguard's Digital Win Matters More Than a Trophy

Updated Category News Views 104

A wealth manager’s website rarely earns applause, but a bad one can sure as hell lose trust fast. Vanguard’s move to No. 1 from No. 3 in the 2025 ranking for advised-investor website satisfaction is worth noticing because it hits the unglamorous part of wealth management that clients actually live with: checking accounts, understanding a plan, moving cash, and...

Continue Reading
Envision’s COP31 Pitch Hinges on Grid Execution, Not Targets

Updated Category News Views 93

A 2,500 GW traffic jam is a rotten place to park climate ambition. Envision Energy used COP31 in Antalya to make the more useful point: clean-power targets mean very little if grids cannot connect, balance and dispatch the electricity. Kane Xu’s message was not another round of flag-waving promises. It was an argument that the constraint has shifted from wanting...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 33

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 218

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 136

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Mindgruve's Tech Hire Puts Sightline Growth in Focus

Updated Category News Views 23

Agency technology hires usually land with all the thunder of a stapler dropping, but this one deserves a closer look. Mindgruve has named Steve Terjeson vice president of technology, handing a former WPP Choreograph executive the job of leading its software development and data engineering teams. The assignment is not vague: push AI innovation, make the proprietary...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating 15 Years of Animal Rescue Corps' Impact

Updated Category News Views 307

Animal Rescue Corps Commemorates 15 Years of Impact Animal Rescue Corps (ARC), a dedicated national nonprofit organization, is excited to celebrate 15 remarkable years of rescuing animals and advocating for their protection. This milestone is not just a reflection of the past but a commitment to continue fighting for animals in need. To honor this achievement, ARC warmly...

Continue Reading
Investigating Investor Claims: Atara Biotherapeutics Update

Updated Category News Views 184

Investor Investigations into Atara Biotherapeutics Recent developments have led to significant interest from investors regarding Atara Biotherapeutics, Inc. (NASDAQ: ATRA). Allegations of possible securities fraud have prompted Pomerantz LLP to investigate the circumstances surrounding the company's practices. If you hold shares in Atara, it's crucial to stay informed...

Continue Reading
Systech's Remarkable 40-Year Journey in Pharma Packaging

Updated Category News Views 329

Systech Celebrates 40 Years of Industry Excellence Marking four decades of innovation, Systech has emerged as a key player in the field of packaging and serialization for the pharmaceutical industry. The company has developed a unique platform that alleviates the common frustrations of working with multiple vendors, providing a comprehensive solution that enhances...

Continue Reading
Empowering Black Artists: The BMAC LIVE Accelerator Initiative

Updated Category News Views 134

The Black Music Action Coalition Launches BMAC LIVE Accelerator Program The Black Music Action Coalition (BMAC) has officially announced the exciting return of its BMAC LIVE Accelerator Program. This initiative is designed to empower Black artists and professionals in the music industry by providing essential resources, training, and mentorship opportunities. BMAC...

Continue Reading
Imperial Petroleum Announces Series A Preferred Share Dividend

Updated Category News Views 212

Imperial Petroleum Inc. Declares Dividend on Series A Preferred Shares ATHENS, Greece – Imperial Petroleum Inc. (NASDAQ: IMPP), a prominent player in the maritime shipping industry, recently made headlines with the announcement of a dividend of $0.546875 per share on its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock. This dividend is notably payable to...

Continue Reading